# AstraZeneca Patients to benefit from further pipeline progress

- Link: https://www.directorstalkinterviews.com/astrazeneca-patients-to-benefit-from-further-pipeline-progress/412796185
- Published: 2019-10-24T07:24:19+01:00
- Author: Amilia Stone

**AstraZeneca **([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
announced its year-to-date and Q3 2019 results.

Year-to-date Product Sales growth of 13% (17% at CER^(1)) to $17,315m included third-
quarter Product Sales of $6,132m (+16%, +18% at CER). The third quarter again saw
all three therapy areas and every sales region produce encouraging performances,
including:

–    The continued performance of new medicines^(2), with sales growth in the quarter
of 62% (+64% at CER) to $2,707m, including new-medicine growth in Emerging Markets
of 85% (90% at CER) to $539m

–    Sales growth by therapy area in the quarter: Oncology +46% (+48% at CER) to
$2,334m, New CVRM^(3) +8% (+11% at CER) to $1,113m and Respiratory +15% (+18% at
CER) to $1,319m

–    Sales growth by region in the quarter: total Emerging Markets sales grew by
25% (29% at CER) to $2,123m, with China sales growth of 35% (40% at CER) to $1,283m,
ahead of longer-term trends. US sales increased by 17% to $2,025m; Europe sales 
continued their return to growth, increasing by 1% (4% at CER) to $1,139m; Japan
sales increased by 31% (27% at CER) to $657m

The Company today upgrades its Product Sales guidance at CER for the year.

**Financial summary**

–    Product Sales increased by 13% in the year to date (17% at CER) to $17,315m.
The performance in the quarter was supported by favourable inventory and gross-to-
net movements which are not expected in the final quarter of the year

–    The Reported Gross Profit Margin increased by one percentage point in the year
to date to 80%, partly reflecting the mix of sales; the Core Gross Profit Margin
increased by one percentage point in the year to date to 81%

–    Reported Operating Expense increased by 11% in the year to date (15% at CER)
to $12,871m and represented 73% of Total Revenue (YTD 2018: 74%). Core Operating
Expense increased by 3% (6% at CER) to $10,537m and represented 59% of Total Revenue(
YTD 2018: 65%), demonstrating a significant improvement in operating leverage

–    Reported R&D Expense increased by 1% in the year to date (5% at CER) to $3,968m.
Core R&D Expense increased by 1% (4% at CER) to $3,826m, partly a result of investment
in the development of the potential new oncology medicine, trastuzumab deruxtecan

–    Reported SG&A Expense increased by 16% (20% at CER) in the year to date to 
$8,656m, due to an increase in legal provisions and revaluation movements on acquisition-
related liabilities in the year to date; Core SG&A Expense increased by 4% (8% at
CER) to $6,464m, primarily reflecting growth in China, as well as ongoing additional
support for new medicines. An update on legal matters and subsequent events is disclosed
in Note 5 and Note 6

–    Reported Other Operating Income and Expense declined by 32% in the year to 
date (31% at CER) to $1,041m; Core Other Operating Income and Expense declined by
7% (6% at CER) to $1,060m

–    The Reported Operating Profit Margin declined in the year to date by one percentage
point (two at CER) to 13%; the Core Operating Profit Margin increased by five percentage
points to 28%

–    The Reported Tax Rate in the year to date was 27% (YTD 2018: 18%); the Core
Tax Rate was 22% (YTD 2018: 19%). The tax rates in the year to date reflected the
geographical mix of profits and the impact of collaboration and divestment activity

–    Reported EPS of $0.79 in the year to date, based on a weighted-average number
of shares of 1,297m, represented a decline of 11% (15% at CER); Core EPS increased
by 39% (38% at CER) to $2.61. In April 2019, the Company completed an issue of 44,386,214
new ordinary shares of $0.25 each at a price of £60.50 per share, resulting in an
increase in share capital of $11m and an increase in share premium of $3,479m, net
of transaction costs of $22m

–    The difference between the Reported and Core EPS year-on-year performance partly
reflected the impact of a favourable $346m legal settlement in YTD 2018 that was
recognised as income in Reported Other Operating Income and Expense. It was also
a result of the aforementioned increase in legal provisions and revaluation movements
on acquisition-related liabilities in 2019

–    The Company today upgrades its Product Sales guidance at CER for the year. 
Product Sales are now expected to increase by a low to mid-teens percentage; the
prior guidance was for a low double-digit percentage increase

**Commercial summary**

**Oncology**

Sales growth of 50% in the year to date (54% at CER) to $6,393m, including:

–    _Tagrisso_ sales of $2,305m, representing growth of 82% in the year to date(
86% at CER). The performance included growth in Emerging Markets of 108% (120% at
CER) to $553m that partly reflected the early-2019 inclusion of _Tagrisso_ as a 
2nd-line treatment for EGFR^(7)-mutated (EGFRm) NSCLC^(8) on the China National 
Reimbursement List (NRDL). _Tagrisso_ is now approved as a 1st-line treatment in
most major markets

–    _Imfinzi_ sales of $1,045m, representing growth of 182% (184% at CER). Commercial
execution and favourable reimbursement decisions supported sales growth outside 
of the US. Europe sales increased significantly to $115m (YTD 2018: $9m), accompanying
encouraging Japan sales of $149m (YTD 2018: $9m)

–    _Lynparza_ sales of $847m, representing growth of 93% (98% at CER). The performance
included growth in the US of 86% to $432m and Emerging Markets of 205% (227% at 
CER) to $101m as the medicine consolidated its leadership position in the poly ADP
ribose polymerase (PARP)-inhibitor class    

–    The performance from more-mature Oncology medicines in the year to date included
a decline in _Faslodex_ sales of 4% (1% at CER) to $726m and a 16% decline in _Iressa_
sales (11% at CER) to $343m. The Company anticipates continued declines for both
medicines, partly reflecting generic _Faslodex_ competition in the US and the pricing
impact on _Iressa_ from centralised procurement in China and the success of _Tagrisso_;
both medicines saw significant declines in the third quarter

–    Oncology sales growth in Emerging Markets of 42% (51% at CER) to $1,665m

**New CVRM**

Sales growth of 11% in the year to date (14% at CER) to $3,207m, including:

–    _Brilinta _sales of $1,153m, representing growth of 22% (26% at CER). The performance
was bolstered by results in Emerging Markets, where sales grew by 50% in the year
to date (59% at CER) to $348m. Patient uptake continued in the treatment of acute
coronary syndrome and high-risk post-myocardial infarction

–    _Farxiga_ sales of $1,124m, with growth of 13% (17% at CER), ahead of the impact
of label updates to reflect results from the DECLARE CV outcomes trial (CVOT). The
level of sales growth in the US was adversely impacted by gross-to-net adjustments;
underlying demand remained strong

–    _Bydureon _sales of $410m, a decline of 8% (7% at CER), partly driven by the
impact of production constraints in the first half for the new _Bydureon BCise_ 
device and declining volumes for the dual-chamber pen

–    New CVRM sales growth in Emerging Markets of 37% (46% at CER) to $835m

**Respiratory**

Sales growth of 9% in the year to date (13% at CER) to $3,854m, including:

–    A _Symbicort_ sales decline of 7% (4% at CER) to $1,783m, reflecting continued
pricing pressure and the impact of managed-market rebates in the US. This was partially
offset by Emerging Markets growth of 10% (18% at CER) to $401m

–    _Pulmicort_ sales growth of 17% (23% at CER) to $1,053m; the majority of _Pulmicort_
sales were in Emerging Markets. Q3 2019 global sales increased by 28% (31% at CER)
to $337m

–    _Fasenra_ sales of $498m, representing growth of 189% (193% at CER). _Fasenra_
leads the medicine class for the treatment of severe eosinophilic asthma by new 
patient share in a number of key markets

–    Respiratory sales growth in Emerging Markets of 24% (31% at CER) to $1,419m

**Emerging Markets**

As the Company’s largest region, at 35% of total Product Sales, Emerging Markets
sales increased by 19% in the year to date (26% at CER) to $6,074m, including:

–    A China sales increase of 30% (37% at CER) to $3,691m. Highlights included:

–     Oncology sales growth of 58% (67% at CER) to $1,023m

–     New CVRM growth of 78% (88% at CER) to $359m

–    An ex-China sales increase of 5% (12% at CER) to $2,382m (Q3 2019: $839m, +
12%, +15% at CER). All regions were in CER sales growth in the year to date, including:(
ex-China) Asia-Pacific, Middle East and Africa, Brazil and Russia

**[Sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
summary**

In the year to date, AstraZeneca was recognised as a global sustainability leader:

–    The Company achieved fourth position overall in the pharmaceutical industry
in the 2019 Dow Jones Sustainability Indices (DJSI). AstraZeneca maintained its 
2018 overall score and achieved a perfect score of 100 in the areas of environmental
reporting, labour-practice indicators, social reporting and health-outcome contribution.
This marked the 18th time that AstraZeneca was included in the indices

–    The Company was again named as a member of the FTSE4Good Index Series, ranking
in the 94th percentile of the healthcare industry, with perfect scores in climate
change, anti-corruption, corporate governance and customer responsibility

Recent developments and progress against the Company’s sustainability priorities
are reported below:

–    Access to healthcare: the Company celebrated the fifth anniversary of its Healthy
Heart Africa (HHA) programme, conducting over 12 million blood-pressure screenings
and identifying over two million elevated readings since its launch in 2014, working
with collaborators across Kenya, Ethiopia, Tanzania and Ghana

–    Environmental protection: AstraZeneca participated in Climate Week, taking 
part in events such as The Climate Group’s ‘Step Up: The Business Case for Greater
Government Ambition’ panel, as the first pharmaceutical-company member of the global
EV100 initiative

–    Ethics and transparency: the Company launched an employee campaign, ‘Speak 
Up – Your Voice Matters’ using internal social-media channels. The campaign encouraged
honest and open dialogue in support of a healthy business culture, where people 
feel able to make their voices heard

A more extensive Sustainability update is provided later in this announcement.

> **Pascal Soriot, Chief Executive Officer at AstraZeneca, commenting on the results
> said**:
> “With AstraZeneca growing at pace, our sales guidance has been upgraded for the
> second consecutive quarter. Another strong performance from our new medicines 
> accompanied impressive results in our key markets, most notably in China, the 
> US and Japan. The performance reinforces our confidence in delivering sustainable
> earnings growth.
> We delivered further positive news for patients. _Lynparza_ demonstrated its potential
> as a treatment for prostate cancer and as an expanded treatment for ovarian cancer.
> _Tagrisso_, _Imfinzi_ and PT010 also had positive data, and we delivered breakthrough
> data in heart failure for _Farxiga_.
> We are continuing to ensure that we capture the benefits of our growth by balancing
> reinvesting in our business, delivering on our sustainability commitments, continuing
> to improve our operating leverage and cash generation.”

Share on:
